Novavax, Inc. (NVAX) belonging to the Medical sector has declined -0.72% and closed its last trading session at $1.38.
The company reported its EPS on 02/27/2017. Currently, the stock has a 1 Year Price Target of $3.29.
The consensus recommendation, according to Zacks Investment research, is 2.67. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2.67 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.67 and 2.67 respectively.
Novavax, Inc. on 02/27/2017 reported its EPS as $-0.21 with the analysts projecting the EPS of the stock as $-0.23. The company beat the analyst EPS Estimate with the difference of $0.02. This shows a surprise factor of 8.7%.
Many analysts have provided their estimated foresights on Novavax, Inc. Earnings, with 7 analysts believing the company would generate an Average Estimate of $-0.17.
Whereas they predicted High and Low Earnings Estimate as $-0.13 and $-0.19 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.29.
Analysts are also projecting an Average Revenue Estimate for Novavax, Inc. as $6.17 Million in the Current Quarter. This estimate is provided by 6 analysts.
The High Revenue estimate is predicted as 9 Million, while the Low Revenue Estimate prediction stands at 4 Million. The company’s last year sales total was 4.22 Million.
For the Current Quarter, the growth estimate for Novavax, Inc. is 41.4%, while for the Next Quarter the stock growth estimate is 44.8%.
The Company got Downgrade by Citigroup on 16-Sep-16 from Buy to Neutral.
Insider Trades for Novavax, Inc. show that the latest trade was made on 30 Jan 2017 where Phillips (Barclay A), the Chief Financial Officer completed a transaction type “Buy” in which 1633 shares were traded at a price of $1.12.
11 Insider Sales transactions were made totaling 5119660 shares traded.
7 analysts projected Price Targets for Novavax, Inc.. The analysts believe that the company stock price could grow as high as $12. The Low Price target projection by analysts is $1.5 and the Mean Price Target is $3.29.
Novavax, Inc. (NVAX) has the market capitalization of $375.25 Million. The company rocked its 52-Week High of $8.49 on Sep 15, 2016 and touched its 52-Week Low of $1.16 on Sep 16, 2016.
The stock has Return on Assets (ROA) of -56.8 percent. Return on Equity (ROE) stands at -329.6% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 9.52 Percent. The company has Beta Value of 1.96 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 3.15% and 7.24%.